PROF earnings
Profound Medical Corp. (PROF) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to FollowTORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2026 Results Conference Call Details: Date: Thursday, May 7, 2026 Time: 4:30 p.m. ET Live Call Dial-in Numbers: 1-800-717-1738 (North America) or 1-646-307-1865
- Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to FollowTORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2025 Results Conference Call Details: Date: Thursday, March 5, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI9b6f
- Profound Medical Reports Strong Third Quarter 2025 Financial ResultsTORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025.Gross margin increased 1,119 basis p
- Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third QuarterTORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. For the quarter ended September 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ag
- Profound Medical Announces Second Quarter 2025 Financial ResultsTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2
- Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to FollowTORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2025 Results Conference Call Details: Date: Thursday, August 14, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BId8
- Profound Medical Announces First Quarter 2025 Financial ResultsTORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q1-2025 revenue growth of 82% over Q1-2024. Profound continued to see a wide variety of prostate disease patients treated by
- Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to FollowTORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
- Profound Medical Announces Fourth Quarter and Full Year 2024 Financial ResultsTORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur
- Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to FollowTORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2024 Results Conference Call Details: Date: Thursday, March 6, 2025 Time: 4:30 p.m. ET Live Call Registration: https://
- Profound Medical Announces Third Quarter 2024 Financial ResultsTORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights Q3-2024 revenue growth of 64% over Q3-2023.Profound continued to see a wide variety of prostate dise
- Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to FollowTORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2024 Results Conference Call Details: Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI0b43a811a8b6
- Profound Medical Announces Second Quarter 2024 Financial ResultsTORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed base grew from 53 at the end of Q1-2024 to 57 as of the end of Q2-2024;
- Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to FollowTORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2024 Results Conference Call Details: Date: Thursday, August 8, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BIbfa8c9bee6c646
- Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue GuidanceTORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed
- Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to FollowTORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2024 Results Conference Call Details: Date:Thursday, May 9, 2024Time:4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI477e53fa85fe419682e13b58f273
- Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to FollowTORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2023 Results Conference Call Details:Date:Thursday, March 7, 2024Time:4:30 p.m. ETLive Call Registration:https://register.vevent.com/register/B
- Profound Medical Announces Third Quarter 2023 Financial ResultsTORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board applicable to the preparation of interim condensed consolidated financial statements, including International Accounting St
- Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to FollowTORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2023 financial results after market close on Thursday, November 2, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2023 Results Conference Call Details: Date:Thursday, November 2, 2023Time:4:30 p.m. ETLive Call Registration:https://register.vevent.com/register/BIe4cb03c9ce9e491187ff1
- Profound Medical Announces Second Quarter 2023 Financial ResultsTORONTO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board applicable to the preparation of interim condensed consolidated financial statements, including International Accounting Standa
- Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to FollowTORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2023 Results Conference Call Details: Date:Wednesday, August 9, 2023Time:4:30 p.m. ETLive Call Registration:https://register.vevent.com/register/BI89a039deab82494a8b815
- Profound Medical Announces First Quarter 2023 Financial ResultsTORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. "We continue to receive resoundingly positive feedback about the four TULSA clinical data presentations that were delivered a
- Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to FollowTORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2023 Results Conference Call Details: Date:Wednesday, May 10, 2023Time:4:30 p.m. ETLive Call Registration:https://register.vevent.com/register/BI314e0d7f1a8048c1a1f4117231
- Profound Medical Announces Fourth Quarter and Full Year 2022 Financial ResultsTORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. "Our U.S. TULSA business, both in terms of installed base growth and existing system utilization, has incr
- Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to FollowTORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2022 Results Conference Call Details: Date:Tuesday, March 7, 2023 Time:4:30 p.m. ET Live Call Registration:https://register.vevent.com/reg
- Profound Medical Announces Third Quarter 2022 Financial ResultsTORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Third Quarter 2022 and Recent Corporate Highlights The Current Procedural Terminology ("CPT®") Category 1 application fo
- Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to FollowTORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2022 Results Conference Call Details: Date:Thursday, November 3, 2022 Time:4:30 p.m. ET Live Call Registration:https://register.vevent.com/register/BI9fe61ff681a946ce8
- Profound Medical Announces Second Quarter 2022 Financial ResultsTORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Second Quarter 2022 and Recent Corporate Highlights Multiple clinical presentations and product demonstrations performed at
- Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to FollowTORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial results after market close on Thursday, August 4, 2022. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2022 Results Conference Call Details: Date:Thursday, August 4, 2022 Time:4:30 p.m. ET Live Call Toll-Free:1-866-374-5140 (PIN: 23122874#)Live Call International:1-4
- Profound Medical Announces First Quarter 2022 Financial ResultsTORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. First Quarter and Recent Corporate Highlights On January 5, 2022, Profound announced the appointment of accomplished global m
- Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to FollowTORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2022 financial results after market close on Monday, May 9, 2022. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2022 Results Conference Call Details: Date: Monday, May 9, 2022 Time: 4:30 p.m. ET Live Call: 1-833-710-1825 (Canada and the United States) 1-929-517-0404 (International
- Profound Medical Announces Fourth Quarter and Full Year 2021 Financial ResultsTORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Full Year 2021 and Recent Corporate Highlights On March 3, 2021, the Company announced the appointment of
- Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to FollowTORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2021 financial results after market close on Thursday, March 3, 2022. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2021 Results Conference Call Details: Date:Thursday, March 3, 2022 Time:4:30 p.m. ET Live Call:1-833-710-1825 (Canada and the United States)
- Profound Medical Announces Third Quarter 2021 Financial ResultsTORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2021. Recent Corporate Highlights On July 29, 2021, the Company participated in A.G.P.'s Virtual MedTech Summer Conference.On September 15, 2021, Profound Lake Street's 5th Annual Best Ideas Growth Conference.On September 30, 2021, the Company participated in the Cantor Virtual Global Healthcare Conference. "Despite facing sector-w
- Profound Medical to Release Third Quarter 2021 Financial Results on November 4 – Conference Call to FollowTORONTO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2021 Results Conference Call Details: Date:Thursday, November 4, 2021 Time:4:30 p.m. ET Live Call:1-800-773-2954 (Canada and the United States) 1-847-413-3731 (Interna
- Profound Medical Announces Second Quarter 2021 Financial ResultsTORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021. Recent Corporate Highlights On April 21, 2021, the Company participated in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference.On May 6, 2021, Profound announced a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc. (TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging services in the Unite